SaNOtize Research and Development Corp.

Founded in 2017 and based in Vancouver, British Columbia, Canada, SaNOtize Research and Development Corp. a. k. a SaNOtize operates as a pharmaceutical company that leverages the antimicrobial properties of nitric oxide (NO), a naturally occurring molecule known to have antibacterial, antifungal, and antiviral properties.

The company was founded by CEO, Dr. Gilly Regev and Chief Scientific Officer Dr. Chris Miller. In August 2022, SaNOtize Research and Development Corp.

raised USD 24 million in Series B funding co-led by new investor Horizons Ventures and returning investor OurCrowd, with participation from another new investor ABC international. The company developed a Nitric Oxide Releasing Solution platform technology to help treat microbial infections such as Covid-19, influenza, and other viruses. The company's therapeutics pipeline includes Nitric Oxide Nasal Spray (NONS) is sold as a medical device in Thailand, Singapore, Hong Kong, Nepal, South Africa, and Germany under the brand VirX, in Israel, Indonesia, and Bahrain under the brand enovid. In India, NONS is available with a prescription under the name FabiSpray.

Other therapeutics in the pipeline include treatment for Chronic sinusitis, diabetic foot ulcer, and nail fungus (onychomycosis. The company plans to use the 2022 funding to expand its research program, including its ongoing global Phase 3 NONS prevention clinical study, recruit up to 3,000 participants in Canada and Sri Lanka, and enhance the clinical development of its other nitric oxide-based therapeutics.